CN109259022A - 一种能快速改善微循环功能的含小分子肽的饮品 - Google Patents
一种能快速改善微循环功能的含小分子肽的饮品 Download PDFInfo
- Publication number
- CN109259022A CN109259022A CN201811401307.7A CN201811401307A CN109259022A CN 109259022 A CN109259022 A CN 109259022A CN 201811401307 A CN201811401307 A CN 201811401307A CN 109259022 A CN109259022 A CN 109259022A
- Authority
- CN
- China
- Prior art keywords
- parts
- people
- microcirculation
- drink
- molecular peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004089 microcirculation Effects 0.000 title claims abstract description 49
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 39
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 16
- 108010035532 Collagen Proteins 0.000 claims abstract description 16
- 229920001436 collagen Polymers 0.000 claims abstract description 16
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 12
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 12
- 241000209140 Triticum Species 0.000 claims abstract description 11
- 235000021307 Triticum Nutrition 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 239000006041 probiotic Substances 0.000 claims abstract description 9
- 235000018291 probiotics Nutrition 0.000 claims abstract description 9
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 8
- 244000068988 Glycine max Species 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 7
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 5
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims abstract description 5
- 244000179886 Moringa oleifera Species 0.000 claims abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- 240000002853 Nelumbo nucifera Species 0.000 claims description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001527 calcium lactate Substances 0.000 claims description 4
- 229960002401 calcium lactate Drugs 0.000 claims description 4
- 235000011086 calcium lactate Nutrition 0.000 claims description 4
- 235000012754 curcumin Nutrition 0.000 claims description 4
- 239000004148 curcumin Substances 0.000 claims description 4
- 229940109262 curcumin Drugs 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 241000238557 Decapoda Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 20
- 230000006872 improvement Effects 0.000 abstract description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 5
- 230000003860 sleep quality Effects 0.000 abstract description 4
- 230000002929 anti-fatigue Effects 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 3
- 210000000653 nervous system Anatomy 0.000 abstract description 3
- 102000005606 Activins Human genes 0.000 abstract description 2
- 108010059616 Activins Proteins 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 239000000488 activin Substances 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 abstract description 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 40
- 230000006870 function Effects 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 14
- 241000220215 Moringa Species 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 230000013872 defecation Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241001669679 Eleotris Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940100688 oral solution Drugs 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000009084 cardiovascular function Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UIMGHSAOLFTOBF-DPAQBDIFSA-N 3beta-Hydroxycholest-4-ene Chemical compound C1CC2=C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 UIMGHSAOLFTOBF-DPAQBDIFSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种能快速改善微循环功能的含小分子肽的饮品,所述改善微循环的饮品将大豆低聚肽、小麦低聚肽、人参肽和骨胶原蛋白肽粉与辣木酵素、益生菌以及其它辅料有机地结合在一起,通过科学合理搭配促进小分子肽在人体内更好地吸收从而快速发挥其功效。本发明所提供的快速改善微循环的饮品能在最短的时间内直接有效增加人体循环动力,激活人体细胞、软化疏通全身血管,活化周身神经,改善微循环,清除体内毒素,辅助人们恢复正常新陈代谢,从而有效改善人体的微循环,例如:它能降低甘油三酯和胆固醇等血脂主要成分的浓度,从而改善心血管系统微循环障碍;它还能提高免疫力、抗疲劳和改善睡眠质量,从而改善神经系统微循环障碍。
Description
技术领域
本发明涉及营养饮品,具体涉及一种能快速改善微循环功能的含小分子肽的饮品。
背景技术
微循环是指人体微动脉和微静脉之间的血液循环,它最根本的功能是进行血液和组织之间的物质交换。人体每个器官和每个组织细胞均要由微循环提供氧气、养料、传递能量、交流信息、排除二氧化碳及代谢废物等。
现代医学研究已证明:人体的衰老、肿瘤的发生、高血压、糖尿病及许多心脑血管等疾病,主要是微循环障碍所致,因此,微循环正常与否是衡量人体健康的重要标志之一。然而,现今人们的生活方式中的各种不良饮食习惯、超重的工作压力及环境污染等都会让各种杂质(例如:胆固醇、酒精、尼古丁、药物残渣和化学残留物等)混浊在人体血液中使血管壁变厚,有时还会堵塞血管,造成血液运行不畅导致微循环障碍,这是导致微循环障碍的最主要外部原因。另一方面,随着年龄的增长,人体的细胞和血液会逐渐衰老,功能也自然随之退化,这是造成微循环障碍内部原因。
人体一旦发生微循环障碍,轻则处于亚健康状态,重则百病从生,例如:脑部发生微循环障碍会造成供血不足,脑细胞得不到充足的氧气和养料,代谢产物不能充分顺利排除,而导致头晕、头痛、失眠、多梦、记忆力下降、神经衰弱、重者会发生脑梗塞、中风等症;心脏发生微循环障碍,引起心肌供血不足,产生胸闷、心慌、心律不齐、心绞痛等冠心病的症状,甚至发生心肌梗死;肺发生微循环障碍时,则会发生胸闷、气短、咳嗽、哮喘、支气管炎等;胃发生微循环障碍,就会引起胃的功能紊乱,营养吸收不良,发生胃炎、溃疡病以及其他胃部病变。内分泌系统发生微循环障碍时,可导致各种激素分泌紊乱,引发甲关腺功能亢进、糖尿病、乳腺炎和小叶增生等;泌尿生殖系统发生微循环障碍时,导致肾炎、肾衰、女性盆腔炎、月经不调、男性前列腺炎、膀胱炎等。
目前虽然可通过一些扩张血管的药物来改善症状,但药物治疗存在一定风险,且只能缓解症状,不能从根本上解决问题。市面上还缺少通过食疗来改善微循环的天然营养品,小分子肽是分子结构介于氨基酸和蛋白质之间的一类化合物,它具有调节机体生理功能和为机体提供营养的双重功效,它几乎影响着人体的一切代谢合成。研究表明:小分子肽具有调节植物神经系统、活化细胞免疫机能、改善心血管功能和抗衰老等生理活性,这为开发肽药物、肽类保健食品提供了理论依据。因此,利用各种小分子肽与其它天然物质结合来开发具有改善微循环的饮品是非常有意义的。
发明内容
本发明的目的在于提供一种能快速改善微循环功能的含小分子肽的饮品。
为了达成上述目的,本发明的解决方案是:
一种能快速改善微循环功能的含小分子肽的饮品,其特征在于,所述饮品的原料含量按重量份数计算如下:胶原蛋白1-3份,白藜芦醇0.2-0.5份,骨胶原蛋白肽粉2-4份,虾青素0.1-0.2份,大豆低聚肽2-5份,小麦低聚肽2-5份,低聚麦芽糖1-2份,乳酸钙0.5-1份,抗性糊精3-5份,人参肽0.5-1份,辣木酵素1-3份,小麦胚芽粉3-6份,益生菌2-5份,姜黄素0.1-0.2份,荷叶提取物2-3份,红枣提取物1-2份。
优选地,所述胶原蛋白为驴皮胶原蛋白。
优选地,所述益生菌为青春双歧杆菌菌粉。
下面对本发明中所使用的主要活性原料和辅料作详细介绍:
胶原蛋白是修复人体受损组织的重要原料物质。当人体真皮层的胶原蛋白被氧化断裂后,对表皮的支撑作用就消失了,因此造成不均一的塌陷,这样皱纹就产生了,而补充胶原蛋白能使肌肤变得细腻和润滑,细小皱纹能得到很好的舒展,肤色有所增白。
白藜芦醇是一种天然的抗氧化剂,抑制血小板凝结和血管舒张,保持血液畅通,具有抗动脉粥样硬化和冠心病,缺血性心脏病,血脂的防治作用。有退烧与止痛作用、心血管保护作用,提升免疫系统活性、抗自由基、抗炎、抗菌、延年益寿。
骨胶原蛋白肽粉是从牛羊等动物皮肤或骨骼中提取分离得来的天然生物活性小分子肽,具有抑制血管紧张素转化酶活性、抑制血小板凝结活性、抗氧化活性及抗肿瘤活性等。
虾青素具有多种生理功效,如在抗氧化性、抗肿瘤、预防癌症、增强免疫力和改善视力等方面都有一定的效果。
大豆低聚肽是大豆的水解产物,其氨基酸组成与大豆蛋白一样,除具有优质蛋白的特点以外,还具有大豆蛋白所不具备的良好的溶解性、稳定性等理化性质,而且具有易吸收和低过敏原性、降低血脂和胆固醇、降低血压、促进矿物质吸收和脂肪代谢及增强体能等多种生理功能。
小麦低聚肽是小麦蛋白粉水解后分离获得的小分子多肽物质,在保持原蛋白营养特性的同时,还具有良好的水溶性、乳化性和配伍性,并且含有丰富的谷氨酰胺;而谷氨酰胺是维持脑氨平衡和作为神经递质的前体物质。
乳酸钙是一种补钙剂,具有促进骨骼及牙齿的钙化形成、维持神经与肌肉的正常兴奋性和降低毛细血管通透性等作用。
青春双歧杆菌具有显著的抗衰老作用,可明显增加血中超氧化物歧化酶(SOD)的活性与含量。从而减少自由基的氧化反应和对人体细胞的损伤,具有延年益寿的功效。青春双歧杆菌还具有降低胆固醇和甘油三酯的作用,使胆固醇转化成人体不吸收的粪甾醇,从粪便排出体外。
低聚麦芽糖除了作为甜味剂之外,对人体内有益的双歧杆菌有强大的增殖作用,净化肠道,促进肠蠕动,防止和解除便秘及腹泻,抑制体内有害菌的繁殖和有毒腐败物质的产生。对分泌体内多种毒素的产气荚膜梭状芽胞杆菌有明显抑制作用,增强免疫力、降低胆固醇和血脂,促进老年人对钙质的吸收,是驻防老年人骨质疏松的有效营养补剂,还可阻断蔗糖被变异链球菌分解,抑制蛀牙。
抗性糊精由淀粉加工而成,是将焙烤糊精的难消化成分用工业技术提取处理并精炼而成的一种低热量葡聚糖,属于低分子水溶性膳食纤维。
人参肽是从人参或人参蛋白质水解产物中获取的具有生物活性功能的小分子肽,具有提高免疫力、抗氧化、抗疲劳、提高或改善性功能、降血糖、降血脂、提高缺氧耐受力、增强抗辐照能力、保肝护肝、清咽等作用;完整保留了人参的营养价值和活性成分,又克服了传统人参服用方法繁琐、难吸收、易上火及不易储存等弊端。
辣木酵素富含多酚及其苷类、总黄酮类、辣木活性多糖,辣木树素、生物碱等数十种对人健康有效成份,它对排除人体健康威胁最大的血糖毒素和血脂毒素并逐步治愈糖尿病和改善“三高”人群亚健康有极大促进作用,清除血液糖毒、脂肪毒素、净化血液的效果,对于高血糖、血管硬化有良好的调治作用。
小麦胚芽又称麦芽粉,营养价值非常的高,含丰富的维生素及蛋白质,其所含的谷胱甘肽能快速清除体内自由基、保护体内细胞不被氧化损伤、延缓衰老和抗疲劳及抗癌功效。此外,小麦胚芽还含有大量的膳食纤维,具有解除便秘、降低血脂、降低餐后血糖等功效,以及减肥、排毒之功能。
姜黄素是从姜科或天南星科中的一些植物的根茎中提取的一种天然物质,具有降血脂、抗肿瘤、抗炎、利胆及抗氧化等作用。
荷叶提取物中含有荷叶碱、荷叶黄酮、柠檬酸及烟酸等物质,具有利尿通便、通肠毒、降脂除油和清暑解热等作用,能明显降低血清中甘油三醇和胆固醇含量,具有调节血脂的保健作用。
红枣提取物中含有的环磷酸腺苷是细胞内参与调节物质代谢和生物学功能的重要物质,它可有效增强免疫力、提高造血机能、加快血液循环、改善心血管功能、保护肝功能、保障睡眠质量、消除过敏症状,目前已广泛应用于肿瘤放化疗恢复期、贫血、心脑血管疾病、肺炎及支气管炎、肝炎、肾炎和肠胃病等疾病的临床营养治疗。
本发明的原理及增益效果如下:
(1)本发明提供了一种能快速改善微循环功能的含小分子肽的饮品,通过科学的选材和合理的搭配:将植物来源的天然小分子肽(大豆低聚肽、小麦低聚肽和人参肽)和动物来源的天然小分子肽(骨胶原蛋白肽粉)与辣木酵素、益生菌、天然抗氧化剂以及其它辅料有机地结合在一起,与含单一小分子肽或单独使用辣木酵素的营养品不同,这样的互补搭配能促进小分子肽和辣木酵素在人体内更好地吸收从而快速发挥其功效。本发明所提供的快速改善微循环的饮品能在最短的时间内直接有效增加人体循环动力,激活人体细胞、软化疏通全身血管,活化周身神经,改善微循环,清除体内毒素,辅助人们恢复正常新陈代谢,例如:能高效增殖肠道内有益菌生长繁殖,抑制肠道内有害菌,修复肠道粘膜,清除淤积毒素,促进肠道的蠕动和自然收缩从而改善消化系统微循环障碍;它还能提高免疫力、抗疲劳和改善睡眠质量,从而改善神经系统微循环障碍;此外,它还能抗氧化,促进新陈代谢和细胞修复,提高人体肌肤光滑细腻,进而达到抗衰老效果。
(2)本发明所提供的能快速改善微循环功能的含小分子肽的饮品的主要活性分均来自天然食材,辅料均为食品行业常用原料,长期服用无任何毒害作用。
具体实施方式
下面进一步结合实施例以详细说明本发明。同样应理解,以下实施例只用于对本发明进行进一步说明,不能理解为对本发明保护范围的限制,示例中具体的质量、反应时间和温度、工艺参数等也仅是合适范围中的一个示例,本领域的技术人员根据本发明的上述内容做出的一些非本质的改进和调整均属于本发明的保护范围。
实施例1-3和对比例1-3
所选原料均为商品化原料,状态均为粉剂,使用前均在洁净区分别过80目筛。按照表1的配料比例制备能快速改善微循环的饮品:
表1
单位:千克 | 实施例1 | 实施例2 | 实施例3 | 对比例1 | 对比例2 | 对比例3 |
胶原蛋白 | 1 | 2 | 3 | 2 | 2 | 2 |
白藜芦醇 | 0.2 | 0.3 | 0.5 | 0.3 | 0.3 | 0.3 |
骨胶原蛋白肽 | 2 | 3 | 4 | 0 | 3 | 3 |
虾青素 | 0.1 | 0.15 | 0.2 | 0.15 | 0.15 | 0.15 |
大豆低聚肽 | 2 | 3 | 5 | 0 | 3 | 3 |
小麦低聚肽 | 2 | 3 | 5 | 0 | 3 | 3 |
低聚麦芽糖 | 1 | 1.5 | 2 | 1.5 | 1.5 | 1.5 |
乳酸钙 | 0.5 | 0.7 | 1 | 0.7 | 0.7 | 0.7 |
抗性糊精 | 3 | 4 | 5 | 4 | 4 | 4 |
人参肽 | 0.5 | 0.7 | 1 | 0 | 0.7 | 0.7 |
辣木酵素 | 1 | 2 | 3 | 2 | 0 | 2 |
小麦胚芽粉 | 3 | 5 | 6 | 5 | 5 | 5 |
青春双歧杆菌 | 2 | 4 | 5 | 4 | 4 | 0 |
姜黄素 | 0.1 | 0.15 | 0.2 | 0.15 | 0.15 | 0.15 |
荷叶提取物 | 2 | 2.5 | 3 | 2.5 | 2.5 | 2.5 |
红枣提取物 | 1 | 1.5 | 2 | 1.5 | 1.5 | 1.5 |
实施例1-3和对比例1-3的制备方法如下:在洁净区内中按重量称取各组分后,送入搅拌机中,搅拌至色泽均一无色差为止得到混合粉料,将混合粉料按照8克每包进行内包分装,转出洁净区后进行外包封装得到洁净区内能快速改善微循环功能的含小分子肽的饮品成品。
本发明所制备能快速改善微循环功能的含小分子肽的饮品的使用方法如下:
每日早晚餐前取饮品一包加入到100毫升温开水中搅拌均匀后服用。
本发明所制备能快速改善微循环功能的含小分子肽的饮品的效果测试如下:
案例1改善肠道微循环测试:
与20家理疗机构合作,选取200名40~60岁年龄层存在便秘问题的人士分为4个组(编号分别为甲组,乙组、丙和丁组)每组50人(男女各25人)进行试用,其中甲组服用实施例2制备的饮品,乙组服用对比例1制备的饮品,丙组服用对比例2制备的饮品,丁组服用对比例3制备的饮品,每天早晚各一次,5日为一个疗程,每天致电使用者询问服用口服液后排便情况,将所收集的调查表数据整理获得使用效果统计数据见表1-表4,其中,服用口服液后每日均至少排便一次且每次排便时间较之前缩短50%以上的记为效果显著,服用口服液后每日均至少排便一次但每次排便时间较之前缩短小于50%的记为效果显著的记为效果一般,服用口服液后排便仍不顺畅记为无效。
表2服用1日效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 31人 | 14人 | 5人 |
对比例1 | 0人 | 3人 | 47人 |
对比例2 | 6人 | 10人 | 34人 |
对比例3 | 5人 | 9人 | 36人 |
表3服用5日效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 42人 | 6人 | 2人 |
对比例1 | 0人 | 4人 | 46人 |
对比例2 | 11人 | 10人 | 29人 |
对比例3 | 9人 | 9人 | 32人 |
表4服用15日效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 47人 | 2人 | 1人 |
对比例1 | 0人 | 8人 | 42人 |
对比例2 | 23人 | 9人 | 18人 |
对比例3 | 18人 | 10人 | 22人 |
表5服用30日效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 49人 | 1人 | 0人 |
对比例1 | 0人 | 9人 | 41人 |
对比例2 | 23人 | 9人 | 18人 |
对比例3 | 18人 | 10人 | 22人 |
由表2-表5可以看出实施例2为本发明所提供的快速改善微循环的饮品的优选方案,服用1日后就有超过50%的使用者肠道微循环得到改善,具体表现为排便顺畅,而服用30日后对肠道微循环的改善率可高达98%,这是因为它将4种小分子肽、辣木酵素和益生菌结合在一起,可以快速清除肠道内淤积毒素,促进肠道的蠕动和自然收缩,高效增殖肠道内有益菌生长繁殖,抑制肠道内有害菌,修复肠道粘膜,从而改善人体肠道微循环,而便秘正是由于肠道微循环发生障碍所引起的;对比例1中没有添加任何小分子肽,结果表明它基本没有改善肠道的效果;对比例2中没有添加辣木酵素,结果表明它改善肠道的速度较慢,效果一般;对比例3中没有添加益生菌,结果表明其改善肠道的速度慢,效果也一般。
案例2改善睡眠测试:
与10家理疗院合作,选取200名35~50岁年龄层失眠人士分为4个组(编号分别为甲组,乙组、丙和丁组)每组50人(男女各25人)进行试用,其中甲组服用实施例2制备的饮品,乙组服用对比例1制备的饮品,丙组服用对比例2制备的饮品,丁组服用对比例3制备的饮品,每天早晚各一次,5日为一个疗程,每天收集分发给使用者的智能手环睡眠数据,将所收集的调查表数据整理获得使用效果统计数据见表6-表9,其中睡眠时间与服用前相比延长超过40%的记为效果显著,睡眠延长时间超过10%低于40%的记为效果一般,睡眠延长时间低于10%的记为无效。
表6服用饮品1日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 26人 | 15人 | 9人 |
对比例1 | 0人 | 2人 | 48人 |
对比例2 | 5人 | 9人 | 36人 |
对比例3 | 6人 | 10人 | 34人 |
表7服用饮品5日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 39人 | 6人 | 5人 |
对比例1 | 0人 | 3人 | 47人 |
对比例2 | 9人 | 10人 | 31人 |
对比例3 | 10人 | 10人 | 30人 |
表8服用饮品10日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 44人 | 4人 | 2人 |
对比例1 | 0人 | 6人 | 44人 |
对比例2 | 12人 | 24人 | 14人 |
对比例3 | 12人 | 27人 | 11人 |
表9服用饮品15日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 48人 | 2人 | 0人 |
对比例1 | 0人 | 9人 | 41人 |
对比例2 | 26人 | 14人 | 10人 |
对比例3 | 29人 | 12人 | 9人 |
由表6-表9可以看出超过50%的人服用本发明所提供的快速改善微循环的饮品一日后睡眠就有了显著的改善,服用15日后对睡眠效果的显著改善率为100%;而服用对比例1的饮品后对睡眠效果基本没有改善作用,服用对比例2和对比例3的饮品后对睡眠的改善速度慢,效果也一般。由此可以看出往小分子肽中添加辣木酵素和益生菌能有助于人体对小分子肽的吸收,从而有助于快速改善人体神经系统微循环,有效改善睡眠质量。
Claims (3)
1.一种能快速改善微循环功能的含小分子肽的饮品,其特征在于,所述饮品的原料含量按重量份数计算如下:胶原蛋白1-3份,白藜芦醇0.2-0.5份,骨胶原蛋白肽粉2-4份,虾青素0.1-0.2份,大豆低聚肽2-5份,小麦低聚肽2-5份,低聚麦芽糖1-2份,乳酸钙0.5-1份,抗性糊精3-5份,人参肽0.5-1份,辣木酵素1-3份,小麦胚芽粉3-6份,益生菌2-5份,姜黄素0.1-0.2份,荷叶提取物2-3份,红枣提取物1-2份。
2.根据权利要求1所述的能快速改善微循环功能的含小分子肽的饮品,其特征在于,所述胶原蛋白为驴皮胶原蛋白。
3.根据权利要求1所述的能快速改善微循环功能的含小分子肽的饮品,其特征在于,所述益生菌为青春双歧杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811401307.7A CN109259022A (zh) | 2018-11-22 | 2018-11-22 | 一种能快速改善微循环功能的含小分子肽的饮品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811401307.7A CN109259022A (zh) | 2018-11-22 | 2018-11-22 | 一种能快速改善微循环功能的含小分子肽的饮品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109259022A true CN109259022A (zh) | 2019-01-25 |
Family
ID=65190528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811401307.7A Pending CN109259022A (zh) | 2018-11-22 | 2018-11-22 | 一种能快速改善微循环功能的含小分子肽的饮品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109259022A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109770150A (zh) * | 2019-03-29 | 2019-05-21 | 郑州新福瑞生物科技有限公司 | 一种改善微循环障碍的功能性固体饮料及其制备方法 |
CN111387393A (zh) * | 2020-05-07 | 2020-07-10 | 北京维泰力特生物医药有限公司 | 一种含有小分子肽、白藜芦醇和花青素的饮料及其制备方法 |
CN111920941A (zh) * | 2020-09-24 | 2020-11-13 | 钟发 | 一种美容抗衰老口服液及其制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1219767A (en) * | 1984-11-23 | 1987-03-31 | Daniel R. Mcsweeney | Tableted beverage composition containing dipeptide sweetener and process |
CN101496575A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种含短肽和益生菌的特殊营养食品配方 |
CN104605353A (zh) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | 适用于手术后肿瘤患者食用的配方食品及其制备方法 |
CN105533753A (zh) * | 2015-12-29 | 2016-05-04 | 徐州市铜山区生命科学研究院 | 一种药食两用防治微循环障碍的复方营养剂 |
CN105942490A (zh) * | 2016-03-30 | 2016-09-21 | 北京森源华诚科技发展有限公司 | 一种防治高血脂高血糖高血压的复合酵素组合物 |
CN106509575A (zh) * | 2016-10-11 | 2017-03-22 | 威海养经堂医药科技有限公司 | 一种根奥多肽固体饮料及制备方法 |
CN107252114A (zh) * | 2017-07-01 | 2017-10-17 | 马南行 | 一种增强免疫力抗衰老的组合物及其制备方法 |
CN107485031A (zh) * | 2017-07-08 | 2017-12-19 | 吴江贤 | 一种含胶原蛋白肽的五谷食品全营养配方 |
CN108112996A (zh) * | 2017-12-12 | 2018-06-05 | 法尔玛国际健康管理有限公司 | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 |
CN108157978A (zh) * | 2017-12-30 | 2018-06-15 | 上海健煌生物科技有限公司 | 一种含牛蒡多糖的调节肠道菌群的多肽组合物及应用 |
-
2018
- 2018-11-22 CN CN201811401307.7A patent/CN109259022A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1219767A (en) * | 1984-11-23 | 1987-03-31 | Daniel R. Mcsweeney | Tableted beverage composition containing dipeptide sweetener and process |
CN101496575A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种含短肽和益生菌的特殊营养食品配方 |
CN104605353A (zh) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | 适用于手术后肿瘤患者食用的配方食品及其制备方法 |
CN105533753A (zh) * | 2015-12-29 | 2016-05-04 | 徐州市铜山区生命科学研究院 | 一种药食两用防治微循环障碍的复方营养剂 |
CN105942490A (zh) * | 2016-03-30 | 2016-09-21 | 北京森源华诚科技发展有限公司 | 一种防治高血脂高血糖高血压的复合酵素组合物 |
CN106509575A (zh) * | 2016-10-11 | 2017-03-22 | 威海养经堂医药科技有限公司 | 一种根奥多肽固体饮料及制备方法 |
CN107252114A (zh) * | 2017-07-01 | 2017-10-17 | 马南行 | 一种增强免疫力抗衰老的组合物及其制备方法 |
CN107485031A (zh) * | 2017-07-08 | 2017-12-19 | 吴江贤 | 一种含胶原蛋白肽的五谷食品全营养配方 |
CN108112996A (zh) * | 2017-12-12 | 2018-06-05 | 法尔玛国际健康管理有限公司 | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 |
CN108157978A (zh) * | 2017-12-30 | 2018-06-15 | 上海健煌生物科技有限公司 | 一种含牛蒡多糖的调节肠道菌群的多肽组合物及应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109770150A (zh) * | 2019-03-29 | 2019-05-21 | 郑州新福瑞生物科技有限公司 | 一种改善微循环障碍的功能性固体饮料及其制备方法 |
CN111387393A (zh) * | 2020-05-07 | 2020-07-10 | 北京维泰力特生物医药有限公司 | 一种含有小分子肽、白藜芦醇和花青素的饮料及其制备方法 |
CN111387393B (zh) * | 2020-05-07 | 2022-09-20 | 北京维泰力特生物医药有限公司 | 一种含有小分子肽、白藜芦醇和花青素的饮料及其制备方法 |
CN111920941A (zh) * | 2020-09-24 | 2020-11-13 | 钟发 | 一种美容抗衰老口服液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101347241B (zh) | 纳米功能健康食品及其加工方法 | |
CN104643250B (zh) | 一种可双向调节体重改善亚健康的固体饮料 | |
CN106072573A (zh) | 一种适用于老年肌肉衰减症食用的特膳食品 | |
CN1927383B (zh) | 迅速降低氧化应激的复方制剂及其制备方法 | |
CN1107666A (zh) | 保健盐 | |
CN102144748A (zh) | 具有排毒护肝养颜功能的五色面制食品 | |
CN109259022A (zh) | 一种能快速改善微循环功能的含小分子肽的饮品 | |
CN105533688A (zh) | 一种辅助降血糖保健软胶囊及其制备方法 | |
CN102362627A (zh) | 虫草保健咖啡 | |
KR101025286B1 (ko) | 다시마의 발효에 의한 다량의 gaba를 함유한 발효산물 및 이를 이용한 기능성 천연 발효조미료와 다시마 발효분말의 제조 방법 | |
CN101396115A (zh) | 一种低聚木糖健胃润肠口服液及其制备方法 | |
KR100549089B1 (ko) | 장기능 및 변비 질환 개선용 건강 기능성식품 | |
CN107802770A (zh) | 平衡代谢系统根治早期ⅱ型糖尿病的中药和保健品 | |
CN109820123A (zh) | 一种改善微循环的植物饮品及其制备方法 | |
CN111713699A (zh) | 燕窝减肥组合物,其功能食品、制备方法及应用 | |
KR102507651B1 (ko) | 전통주 효모 함유 천연발효효소복합액을 이용한 숙취해소, 알콜성간질환 또는 간기능 개선용 멀꿀발효물과 그 제조방법 | |
KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
CN102511876A (zh) | 山楂红枣浓浆 | |
CN105176773A (zh) | 一种调节血糖的南瓜酒及其制作方法 | |
CN109730222A (zh) | 酵素复合液及其保健饮料 | |
KR102131341B1 (ko) | 탈모 예방, 발모 촉진, 및 두피 개선 효과가 우수한 건강 선식 제조 방법 | |
KR20190118720A (ko) | 사철쑥을 주성분으로 하는 기능성 및 친환경성 돼지사료용 보조제와 그 제조방법, 그리고 이를 이용한 돼지사육방법 및 그 돈육 | |
CN109363164A (zh) | 一种能改善微循环的含小分子肽的口服液及其制备方法 | |
CN106035686A (zh) | 超级藜麦养生植物奶 | |
KR100734944B1 (ko) | 젖산칼슘 및 미강을 주재로 한 기능성 건강식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190125 |